Article
Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.
Clinical lung cancer - 1 Jun 2022
Zhang Lihong, Yang Xia, Ming Zongjuan, Shi Jie, Lv Xin, Li Wei, Yuan Bo, Chen Yang, Liu Boxuan, Qin Kai, Liu Jiamin, Wei Qingbo, Gu Dejian, Chen Rongrong, Yuan Mingming, Cui Jean, Ou Sai-Hong Ignatius, Yang Shuanying
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) T854A is an uncommon exon 21 mutation in patients with non-small cell lung cancer (NSCLC). It was first reported in samples collected after first generation EGFR tyrosine kinase inhibitor (TKI) treatment as an acquired resistant mutation to first generation EGFR-TKI. The efficacy of osimertinib, a third generation EGFR-TKI, in these patients was not clear....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.